Newswire (Published: Tuesday, January 17, 2017, Received: Friday, January 13, 2017, 1:57:29 AM CST)

Word Count: 434

New Prostate Cancer Study Findings Recently Were Reported by Researchers at University of Palermo (Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study)

By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Oncology - Prostate Cancer have been published. According to news reporting originating from Palermo, Italy, by NewsRx correspondents, research stated, "The present study aims to evaluate the efficacy of cabazitaxel in combination with prednisone treatment in Italian patients affected by hormone-refractory metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel plus prednisone. Thirty patients with mCRPC were enrolled between June 2013 and January 2016 (the last follow-up was in January 2016)."

Our news editors obtained a quote from the research from the University of Palermo, "Cabazitaxel was used according to the summary of product characteristics and administered at a dose of 25 mg/m2 every 3 weeks plus oral prednisone at a dose of 5-mg tablets twice a day continuously. The reduction in serum prostate-specific antigen (PSA) was the primary endpoint while reducing pain, safety, progression-free survival, response rate and overall survival (OS) were secondary endpoints. Cabazitaxel was well tolerated, showing a manageable toxicity profile, associated with a modest objective response rate and a good reduction in PSA levels. Only 12 patients (40%) had a partial response, 10 patients (33%) showed stabilization of disease and 8 (27%) experienced disease progression. The median OS was 14.8 months (95% CI: 11.6-19.8). The linear regression analysis revealed that PSA response was an important predictor of OS, showing a positive correlation with OS (b=0.377, p<0.01)."

According to the news editors, the research concluded: "Three-week treatment with cabazitaxel was found to be valid and was a well-tolerated treatment option for patients with mCRPC after a first-line docetaxel treatment."

For more information on this research see: Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study. Oncology, 2016;():. (Karger - www.karger.com/; Oncology - content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=223857)

The news editors report that additional information may be obtained by contacting G. Cicero, Dept. of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy. Additional authors for this research include R. De Luca, P. Dorangricchia, A. Galvano, G. Lo Re, V. Serretta, N. Dispensa and F. Dieli (see also Oncology - Prostate Cancer).

Keywords for this news article include: Italy, Europe, Palermo, Oncology, Prostate Cancer, Prostatic Neoplasms, Enzymes and Coenzymes, Prostate Specific Antigen.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Places

Southern Europe
Italy
Europe
Palermo

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research